300 related articles for article (PubMed ID: 29751116)
1. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
[TBL] [Abstract][Full Text] [Related]
2. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
[TBL] [Abstract][Full Text] [Related]
4. Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.
Monahan K; Kleman A; Thapa B; Szabo A; D'Souza A; Dhakal B; Jerkins JH; Pasquini MC; Hamadani M; Hari PN; Chhabra S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2229-2236. PubMed ID: 32920204
[TBL] [Abstract][Full Text] [Related]
5. Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and alkeran in multiple myeloma autologous transplantation.
Aljitawi OS; Ganguly S; Abhyankar SH; Ferree M; Marks R; Pipkin JD; McGuirk JP
Bone Marrow Transplant; 2014 Aug; 49(8):1042-5. PubMed ID: 24911220
[TBL] [Abstract][Full Text] [Related]
6. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
7. Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma.
Miller KC; Gertz MA; Buadi FK; Hayman SR; Wolf RC; Lacy MQ; Dispenzieri AA; Dingli D; Kapoor P; Gonsalves WI; Kourelis T; Hogan WJ; Kumar SK
Bone Marrow Transplant; 2019 Apr; 54(4):587-594. PubMed ID: 30116014
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the adverse effects of melphalan formulations.
Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM
J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Pai AA; Devasia AJ; Panetta JC; Mani S; Stallon Illangeswaran RS; Mohanan E; Balakrishnan B; Lakshmi KM; Kulkarni U; Aboobacker FN; Korula A; Abraham A; Srivastava A; Mathews V; George B; Balasubramanian P
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):130-135.e1. PubMed ID: 31791694
[TBL] [Abstract][Full Text] [Related]
10. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.
Barta SK; Jain R; Mazumder A; Carter J; Almanzar L; Browne R; Shahnaz S; Elkind R; Kaminetzky D; Battini R; Derman O; Kornblum N; Verma A; Braunschweig I
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):650-657. PubMed ID: 28684379
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
Khan AM; Yucebay F; Zhao Q; Umyarova E; Cottini F; Bumma N; Rosko A; Benson D; Sharma N; Efebera Y; Devarakonda S
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e85-e96. PubMed ID: 36411211
[TBL] [Abstract][Full Text] [Related]
13. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
14. Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach.
Blanes M; Lahuerta JJ; González JD; Ribas P; Solano C; Alegre A; Bladé J; San Miguel JF; Sanz MA; de la Rubia J
Biol Blood Marrow Transplant; 2013 Jan; 19(1):69-74. PubMed ID: 22897964
[TBL] [Abstract][Full Text] [Related]
15. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Wolf RC; Kumar SK; Gertz MA
Bone Marrow Transplant; 2019 Jul; 54(7):1077-1081. PubMed ID: 30390060
[TBL] [Abstract][Full Text] [Related]
18. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
Mark TM; Reid W; Niesvizky R; Gergis U; Pearse R; Mayer S; Greenberg J; Coleman M; Van Besien K; Shore T
Biol Blood Marrow Transplant; 2013 May; 19(5):831-7. PubMed ID: 23454184
[TBL] [Abstract][Full Text] [Related]
20. Final outcomes of escalated melphalan 280 mg/m
Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH
Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
